- Home
- EVT vs BEAM Comparison
EVT vs BEAM Comparison
Compare EVT & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVT
- BEAM
- Stock Information
- Founded
- EVT 2003
- BEAM 2017
- Country
- EVT United States
- BEAM United States
- Employees
- EVT N/A
- BEAM N/A
- Industry
- EVT Finance Companies
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EVT Finance
- BEAM Health Care
- Exchange
- EVT Nasdaq
- BEAM Nasdaq
- Market Cap
- EVT 1.8B
- BEAM 1.9B
- IPO Year
- EVT N/A
- BEAM 2020
- Fundamental
- Price
- EVT $24.60
- BEAM $28.58
- Analyst Decision
- EVT
- BEAM Buy
- Analyst Count
- EVT 0
- BEAM 10
- Target Price
- EVT N/A
- BEAM $47.67
- AVG Volume (30 Days)
- EVT 121.5K
- BEAM 1.0M
- Earning Date
- EVT 01-01-0001
- BEAM 11-05-2024
- Dividend Yield
- EVT 7.72%
- BEAM N/A
- EPS Growth
- EVT N/A
- BEAM N/A
- EPS
- EVT N/A
- BEAM N/A
- Revenue
- EVT N/A
- BEAM $349,643,000.00
- Revenue This Year
- EVT N/A
- BEAM N/A
- Revenue Next Year
- EVT N/A
- BEAM $10.82
- P/E Ratio
- EVT N/A
- BEAM N/A
- Revenue Growth
- EVT N/A
- BEAM 328.73
- 52 Week Low
- EVT $18.70
- BEAM $20.84
- 52 Week High
- EVT $23.82
- BEAM $49.50
- Technical
- Relative Strength Index (RSI)
- EVT 36.30
- BEAM 56.55
- Support Level
- EVT $24.56
- BEAM $27.02
- Resistance Level
- EVT $25.62
- BEAM $31.00
- Average True Range (ATR)
- EVT 0.24
- BEAM 1.76
- MACD
- EVT -0.12
- BEAM 0.13
- Stochastic Oscillator
- EVT 7.52
- BEAM 59.12
About EVT Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest
EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND is a diversified, closed-end management investment company. Its objective is to provide a high level of after-tax total return consisting mainly of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of electric utilities, energy equipment and services, food products, health care providers and services, internet software and services, and other areas.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.